RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. (IST:RTALB)
Turkey · Delayed Price · Currency is TRY 3.630
-0.080 (-2.16%)
Last updated: Jun 3, 2026, 3:07 PM GMT+3
IST:RTALB Income Statement
Financials in millions TRY. Fiscal year is January - December.
Millions TRY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 253.76 | 239.56 | 207.58 | 138.51 | 191.3 | 384.34 | |
Revenue Growth (YoY) | 49.87% | 15.41% | 49.87% | -27.59% | -50.23% | 66.79% |
Cost of Revenue | 166.29 | 158.26 | 153.94 | 112.71 | 126.73 | 228.46 |
Gross Profit | 87.47 | 81.3 | 53.64 | 25.8 | 64.57 | 155.88 |
Selling, General & Admin | 59.67 | 61.34 | 49.63 | 44.92 | 54.89 | 40.54 |
Research & Development | 36.22 | 37.07 | 29.05 | 21.46 | 14.23 | 16.6 |
Other Operating Expenses | -1.39 | 0.7 | 30.21 | 9.28 | 11.05 | 3.95 |
Operating Expenses | 94.5 | 99.11 | 108.89 | 75.66 | 80.17 | 61.09 |
Operating Income | -7.03 | -17.8 | -55.24 | -49.86 | -15.6 | 94.79 |
Interest Expense | -45.67 | -71.14 | -102.1 | -29.44 | -32.18 | -19.73 |
Interest & Investment Income | 143.6 | 224.24 | 96.85 | 126.42 | 76.02 | 19.58 |
Earnings From Equity Investments | 582.22 | 1,105 | 156.44 | -61.23 | 280.78 | 46.86 |
Currency Exchange Gain (Loss) | -0.85 | -0.85 | 9.65 | 46.38 | 79.98 | 6.88 |
Other Non Operating Income (Expenses) | -69.51 | 12.12 | -107.25 | -133.37 | -213.34 | -0.18 |
EBT Excluding Unusual Items | 602.76 | 1,251 | -1.65 | -101.1 | 175.66 | 148.21 |
Gain (Loss) on Sale of Investments | 21.04 | -1.91 | -65.97 | -3.66 | -2.79 | -0.85 |
Pretax Income | 623.8 | 1,249 | -67.62 | -104.76 | 172.87 | 147.36 |
Income Tax Expense | 322.24 | 368.16 | -135.99 | -1.6 | 36.55 | 20.06 |
Earnings From Continuing Operations | 301.56 | 881.18 | 68.37 | -103.16 | 136.32 | 127.3 |
Minority Interest in Earnings | - | - | - | - | -155.95 | -12.83 |
Net Income | 301.56 | 881.18 | 68.37 | -103.16 | -19.62 | 114.47 |
Net Income to Common | 301.56 | 881.18 | 68.37 | -103.16 | -19.62 | 114.47 |
Net Income Growth | 215.75% | 1188.82% | - | - | - | 87.87% |
Shares Outstanding (Basic) | - | 500 | 500 | 500 | 500 | 500 |
Shares Outstanding (Diluted) | - | 500 | 500 | 500 | 500 | 500 |
Shares Change (YoY) | - | -0.03% | 0.03% | - | - | 4.81% |
EPS (Basic) | - | 1.76 | 0.14 | -0.21 | -0.04 | 0.23 |
EPS (Diluted) | - | 1.76 | 0.14 | -0.21 | -0.04 | 0.23 |
EPS Growth | - | 1189.25% | - | - | - | 79.25% |
Free Cash Flow | 92.32 | 120.97 | -236.79 | 23.93 | -0.77 | 47.35 |
Free Cash Flow Per Share | - | 0.24 | -0.47 | 0.05 | -0.00 | 0.10 |
Gross Margin | 34.47% | 33.94% | 25.84% | 18.63% | 33.76% | 40.56% |
Operating Margin | -2.77% | -7.43% | -26.61% | -36.00% | -8.15% | 24.66% |
Profit Margin | 118.84% | 367.83% | 32.94% | -74.48% | -10.26% | 29.78% |
Free Cash Flow Margin | 36.38% | 50.50% | -114.07% | 17.28% | -0.40% | 12.32% |
EBITDA | 21.85 | 9.17 | -33.29 | -33.85 | 6.66 | 98.74 |
EBITDA Margin | 8.61% | 3.83% | -16.04% | -24.44% | 3.48% | 25.69% |
D&A For EBITDA | 28.89 | 26.97 | 21.95 | 16.01 | 22.26 | 3.95 |
EBIT | -7.03 | -17.8 | -55.24 | -49.86 | -15.6 | 94.79 |
EBIT Margin | -2.77% | -7.43% | -26.61% | -36.00% | -8.15% | 24.66% |
Effective Tax Rate | 51.66% | 29.47% | - | - | 21.14% | 13.61% |
Advertising Expenses | - | - | - | 0.02 | 0.02 | 1.18 |